Stephen Chelko | Toxicology and Pharmaceutical Science | Innovative Research Award

Innovative Research Award

Stephen Chelko
Florida State University College of Medicine

Stephen Chelko
Affiliation Florida State University College of Medicine
Country United States
Scopus ID 54973874200
Documents 47
Citations 1,649
h-index 18
Subject Area Toxicology and Pharmaceutical Science
Event International Invention Awards
ORCID 0000-0003-1675-5945

Stephen Chelko is a researcher affiliated with the Florida State University College of Medicine whose documented scholarly profile is associated with toxicology and pharmaceutical science. Available bibliometric information records 47 documents, 1,649 citations, and an h-index of 18, providing a quantitative basis for assessing research visibility and scholarly influence. [1]

Abstract

Stephen Chelko is a researcher associated with Florida State University College of Medicine and the fields of toxicology and pharmaceutical science. His indexed scholarly record comprises 47 documents, 1,649 citations, and an h-index of 18, according to the supplied Scopus profile information. These indicators provide a measurable basis for describing his research visibility and citation impact within scholarly databases. His profile may be considered in the context of recognition for innovative research, particularly where scientific investigation, translational relevance, and contribution to biomedical knowledge are central criteria. The Innovative Research Award provides a framework for highlighting documented scholarly achievement and research significance.

Keywords

Stephen Chelko; Innovative Research Award; toxicology; pharmaceutical science; biomedical research; Florida State University College of Medicine; research impact; scholarly publications; citation analysis; translational science.

Introduction

Academic recognition commonly considers the quality, relevance, originality, and influence of a researcher’s scholarly work. In this context, Stephen Chelko’s documented profile combines research activity in toxicology and pharmaceutical science with measurable bibliometric indicators. The available Scopus record identifies 47 documents, 1,649 citations, and an h-index of 18. [1]

Research Profile

Chelko’s stated subject area is Toxicology and Pharmaceutical Science, positioning his scholarly profile within disciplines concerned with biological effects, therapeutic development, pharmaceutical research, and related biomedical questions. His affiliation with Florida State University College of Medicine further places this work within an academic medical environment. [4]

Research Contributions

The available information supports describing Chelko’s contribution through his documented publication record and citation footprint rather than assigning unsupported claims about individual discoveries. Forty-seven indexed documents indicate sustained scholarly output, while the recorded citation count suggests that his published research has been referenced by subsequent academic literature. [1]

Publications

The supplied researcher profile reports 47 documents indexed in Scopus. Because complete publication titles, journals, publication years, and article-level DOI information were not supplied, this page does not attribute individual papers or DOI records without verification. The Scopus author profile provides the appropriate source for reviewing the complete indexed publication record. [1]

Research Impact

Research impact can be assessed through several complementary dimensions, including scholarly citations, publication continuity, disciplinary relevance, and potential contribution to scientific practice. Chelko’s reported 1,649 citations and h-index of 18 provide quantitative indicators of scholarly visibility, although bibliometric measures should be interpreted alongside qualitative assessment of research originality and significance. [1]

Award Suitability

The documented research profile is relevant to an Innovative Research Award because it demonstrates sustained scholarly activity in a biomedical subject area and a measurable citation record. Final award suitability should nevertheless depend on the official nomination criteria, verified publications, originality of contributions, supporting evidence, and independent evaluation by the responsible award committee. [5]

Conclusion

Stephen Chelko’s supplied academic profile presents a researcher working in toxicology and pharmaceutical science, affiliated with Florida State University College of Medicine. The reported record of 47 documents, 1,649 citations, and an h-index of 18 provides a measurable foundation for academic recognition. These indicators should be considered together with verified research quality and innovation.

References

  1. Elsevier. (n.d.). Scopus author details: Stephen Chelko, Author ID 54973874200. Scopus.
    https://www.scopus.com/pages/authors/54973874200
  2. ORCID. (n.d.). Stephen Chelko, ORCID iD 0000-0003-1675-5945. ORCID.
    https://orcid.org/0000-0003-1675-5945
  3. Google Scholar. (n.d.). Stephen Chelko — Google Scholar profile.
    https://scholar.google.com/citations?hl=en&user=5Hq6SM0AAAAJ
  4. Journal article. (2019.). Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy.
    https://doi.org/10.1161/CIRCULATIONAHA.119.040676
  5. International Invention Awards. (2026.). Official Award Information.
    https://inventionawards.org/

Lee Jia | Pharmacy | Research Excellence Award

Prof. Lee Jia | Pharmacy | Research Excellence Award

Distinguished Professor and Director in Henan University, United States

Prof. Lee Jia is a highly accomplished pharmacologist with a strong academic foundation, earning his Ph.D. in Pharmacology from the State University of New York under Nobel Laureate Robert F. Furchgott and completing postdoctoral research at Duke University Medical Center in Durham, North Carolina. He currently serves as Distinguished Professor at The First Affiliated Hospital of Henan University and has held key leadership roles including Director of the Marine Drug R&D Center at Minjiang University and founding director of a cancer metastasis research center at Fuzhou University. His international career includes senior scientific positions at the National Cancer Institute, National Institutes of Health, and collaborations with institutions such as University of Geneva and Technological University Dublin. He is widely recognized for contributions to pharmacology, toxicology, nanomedicine, and cancer research, earning distinctions such as Fellow of the American Association of Pharmaceutical Scientists, Fellow of the Academy of Toxicological Sciences, and selection among the world’s top 2% scientists by Stanford University and Elsevier. He has received numerous prestigious honors including major national innovation awards in China, international research recognitions, and leadership roles in scientific societies such as the Chinese Pharmaceutical Association. In addition to his research impact, he has made extensive contributions as an editor, reviewer, and scientific organizer across leading journals and global conferences, shaping advancements in drug discovery and translational medicine.

Citation Metrics (Scopus)

15000
12000
9000
6000
3000
100
0

Citations
13224

Documents
226

h-index
55

Citations

Documents

h-index

View Scopus Profile

Featured Publications

 

Zsuzsanna Suba | Cancer research | Breakthrough Research Award

Prof. Dr. Zsuzsanna Suba | Cancer research | Breakthrough Research Award

National Institute of Oncology, Budapest, Hungary

Profile

Orcid

🎓 Early Academic Pursuits

Prof. Dr. Zsuzsanna Suba embarked on her academic journey at the Semmelweis University of Medicine, earning her Doctor of Medicine in 1971. Her early interest in both general and oral pathology led her to pursue multiple certifications: Board certification in Pathology (1975), Dentistry and Stomatology (1986), and Oral Pathology (Sheffield, UK, 1987). She further advanced her academic credentials by completing a Ph.D. in 1994 and attaining the Habilitated Medical Science (Habil.Med.Sci.) degree in 2004, marking her as a leading expert in her field.

🩺 Professional Endeavors

Prof. Suba's career commenced in 1971 as an Assistant Professor at the 1st Institute of Pathology and Experimental Cancer Research at her alma mater. She then led the Oral Pathology Division within the Department of Oral and Maxillofacial Surgery at Semmelweis University from 1982 to 2011. In 2004, she was officially named Professor of Oral Pathology. Her final academic post was at the National Institute of Oncology, where she served as Professor of Pathology from 2011 until becoming Professor Emeritus in 2017, reflecting her decades-long contribution to academic medicine.

🧬 Contributions and Research Focus

Prof. Suba’s research has significantly shaped understanding in several niche yet vital domains of pathology. Her early work investigated cell proliferation kinetics and virus-induced experimental tumors. She later pioneered studies into the pathology of bone replacement in the oral and maxillofacial region, and the clinical and pathological evaluation of chemotherapy outcomes in oral cancers. Notably, she explored the correlations between metabolic disorders (like type-2 diabetes, insulin resistance, and obesity) and cancer incidence, particularly oral and breast cancers. Her groundbreaking research highlighted the hormonal mechanisms involved in tumor progression, the role of estrogen signaling in cancer risk, and even proposed a genome-stabilizing therapeutic model for breast cancer cases.

🌍 Impact and Influence

Prof. Suba’s research has had a substantial impact on the epidemiological and hormonal understanding of cancer biology, especially in women’s health. Her bold interpretations of the paradoxes in antiestrogen treatments in breast cancer, and her promotion of causal therapy over symptomatic treatment, have sparked meaningful discourse in oncological and hormonal therapy communities. Her findings bridge molecular biology, pathology, endocrinology, and clinical practice, positioning her as a multidisciplinary influencer in medical science.

📈 Academic Citations and Publications

With 128 peer-reviewed articles accumulating a total impact factor of 122.647, Prof. Suba has maintained a strong presence in the scientific literature. She has authored 12 books, 42 book chapters—many in English—and accumulated 1,230 independent citations as a first or last author. These achievements speak volumes about the relevance and longevity of her scientific contributions.

🖥️ Technical and Research Skills

Her academic career has been deeply rooted in molecular and surgical pathology techniques, including histopathological diagnostics, tumor cell kinetic analysis, and clinical trials of chemotherapy and hormone therapy outcomes. Her interdisciplinary acumen allows her to integrate pathology, biochemistry, endocrinology, and epidemiology in both laboratory and clinical research contexts.

👩‍🏫 Teaching Experience and Recognition

A beloved educator, Prof. Suba has been honored multiple times for her teaching excellence. She received the Teacher’s Award from Semmelweis University (1998) and again in 2008, this time chosen directly by students. She is known for her dedicated mentorship, ability to simplify complex medical content, and commitment to fostering critical thinking in future clinicians and researchers.

🏅 Honors and Awards

Throughout her illustrious career, she has been decorated with prestigious awards such as the MOTESZ Award for Young Researchers (1976), the Markusovszky Award (1993), and the recent Distinguished Cancer Treatment Innovation Award (2024) from Scifax. These accolades recognize both her innovative research and her lifelong dedication to cancer pathology.

🌟 Legacy and Future Contributions

Now serving as Professor Emeritus, Prof. Suba remains a venerated figure in oncology and pathology. Her visionary work on hormonal and metabolic links to cancer continues to guide current investigations. Her legacy lies not only in her scientific outputs but also in the inspired careers of countless students and clinicians she mentored. Her genome-stabilization framework offers a promising direction for personalized cancer therapy, and future researchers will undoubtedly build upon her foundational insights for decades to come.

Selected Publications

  • Suba Zsuzsanna (2024)
    DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care
    Cancers (Basel), 16(8):1573. April 19, 2024.

  • Suba Zsuzsanna (2024)
    Estrogen Regulated Genes Compel Apoptosis in Breast Cancer Cells, Whilst Stimulate Antitumor Activity in Peritumoral Immune Cells in a Janus‑Faced Manner
    Current Oncology, 31(9):4885–4907. August 24, 2024.

  • Suba Zsuzsanna (2023)
    Rosetta Stone for Cancer Cure: Comparison of the Anticancer Capacity of Endogenous Estrogens, Synthetic Estrogens and Antiestrogens
    Oncology Reviews, 17:10708 (eCollection). April 19, 2023.

  • Suba Zsuzsanna (2020)
    Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen‑Responsive Cancer Cells via Activating Mutations
    Journal of Oncology & Therapy (or equivalent publication). 2020.

  • Suba Zsuzsanna (2018)
    Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors
    Recent Patents on Anticancer Drug Discovery, 13(4):428–444. 2018.